Welcome to our dedicated page for Pro-Dex Colo news (Ticker: PDEX), a resource for investors and traders seeking the latest updates and insights on Pro-Dex Colo stock.
Pro-Dex, Inc. (NASDAQ: PDEX) is a surgical and medical instrument manufacturer that focuses on autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used mainly in the orthopedic, thoracic, and maxocranial facial markets. The Pro-Dex news stream on this page aggregates company-issued press releases and other coverage so readers can follow how its powered surgical instrument business develops over time.
Company news frequently centers on financial results and operating performance. Pro-Dex regularly announces quarterly and annual results, often highlighting changes in net sales, gross profit, operating income, and the impact of product mix and costs such as tariffs. These updates commonly explain how shipments of next generation orthopedic handpieces, repair revenue for legacy handpieces, and sales of thoracic drivers contribute to revenue trends, especially in relation to the company’s largest customer.
Another recurring theme in Pro-Dex news is customer and contract activity. The company has reported contract amendments and extensions with its largest customer, including multi-year extensions with minimum purchase volumes. Releases also discuss enhanced repair programs for orthopedic handpieces and the ramp-up of production shipments for new generations of devices.
Pro-Dex news items may also cover corporate governance and capital matters, such as proxy statements, annual shareholder meetings, equity incentive plan amendments, and executive or director compensation decisions disclosed via Form 8-K. In addition, the company has issued communications clarifying that its Nasdaq-listed common stock under the symbol PDEX is not affiliated with Polkadex, which uses the same symbol on certain crypto exchanges.
Investors and followers of PDEX can use this page to review a chronological record of Pro-Dex announcements, including earnings releases, contract updates, and governance disclosures, all in one place.
Pro-Dex reported Q3 fiscal 2022 results, revealing a 21% decline in net sales, totaling $9.3 million, primarily due to decreased thoracic driver sales. Gross profit fell 35% to $2.9 million, attributed to increased component costs amid supply chain challenges. Operating expenses decreased 27% to $1.9 million. Net income dropped 78% to $462,000 or $0.12 per diluted share. However, year-to-date sales increased 3% to $29.4 million. CEO Van Kirk expressed optimism for Q4, citing a healthy backlog and secured components.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a robust fiscal 2022 second quarter with net sales up 23% to $10.2 million, driven by orthopedic surgical handpiece sales. Gross profit rose 31% to $3.4 million, and operating expenses declined by 13% to $1.8 million. However, net income fell to $925,000 ($0.25 per diluted share) compared to $1.8 million ($0.44) from the same quarter last year. Looking ahead, Pro-Dex warns of supply chain challenges that could reduce net sales in the upcoming quarters but remains optimistic about long-term prospects.
Pro-Dex, Inc. (NasdaqCM:PDEX) reported a 16% increase in net sales for Q1 fiscal 2022, totaling $10.0 million compared to $8.6 million in Q1 2021. The growth stemmed from higher sales of surgical handpieces and CMF drivers, though sales of a thoracic driver decreased. Gross profit fell by $47,000, with a margin of 34% down from 40%. Operating expenses rose $184,000, while net income decreased to $1.1 million, or $0.28 per share. The company is advancing internal projects and preparing to relocate employees to a new facility.
Pro-Dex reported Q4 2021 net sales of $9.4 million, a 15% decrease from $11.1 million in Q4 2020, primarily due to lower medical device sales following two previous product launches. Gross profit fell by 27% to $3.1 million, driven by decreased sales and price concessions. Operating expenses increased by 21% to $2.5 million. Yearly results showed a 9% sales increase to $38 million, with a slight gross profit rise to $13.6 million. However, net income for the year decreased to $4.5 million from $6.1 million, attributed to higher operating expenses and R&D investments.
Pro-Dex reported a 38% increase in net sales for Q3 FY2021, reaching $11.7 million, driven by strong performance in thoracic drivers. Gross profit also rose 37% to $4.4 million. Net income increased to $2.0 million ($0.50 per diluted share) from $1.2 million ($0.30 per diluted share) year-over-year. However, operating expenses surged by 67% due to heightened investment in product development. For the nine months ended March 31, 2021, sales rose 21% to $28.6 million, with net income stable at $3.6 million. The CEO expressed pride in team performance amid challenges during the pandemic.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a 4% increase in net sales for the second quarter of fiscal 2021, totaling $8.3 million, driven by new product sales. However, gross profit declined 9% to $2.6 million due to under-absorbed fixed manufacturing costs. Operating expenses surged 74% to $2.1 million as the company invested in R&D and administrative functions. Net income fell to $337,000 or $0.08 per diluted share, down from $1.2 million or $0.31 per diluted share a year earlier. Year-to-date net sales grew 11% to $16.9 million.
Pro-Dex reported a 19% increase in net sales for Q1 fiscal 2021, totaling $8.6 million, up from $7.2 million in Q1 fiscal 2020. The gross profit rose 25% to $3.5 million, with a gross margin of 40%. Operating expenses increased by $637,000, reflecting investments in R&D for new product launches. Net income for the quarter was $1.3 million, or $0.32 per diluted share, compared to $1.1 million or $0.27 in the prior year. CEO Richard Van Kirk expressed optimism about future product releases, including a new ENT shaver and CMF driver.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a significant increase in net sales for Q4 2020, rising 59% to $11.1 million, attributed to new product launches and a $1.7 million increase in revenue from its largest customer. Gross profit surged 69%, reaching $4.3 million, while net income rose to $2.5 million, or $0.64 per diluted share. For the fiscal year, net sales were up 28% at $34.8 million, with net income increasing to $6.1 million. Operating expenses also grew by 27%, reflecting higher personnel costs. The company maintains a cautious outlook amid the ongoing COVID-19 pandemic.